So 13 years of trial data and analysis in 2700 words??? Lancet makes more sense in every way. Maybe also I prefer this venue as well. Of course my preference is of ZERO importance!!
On the other hand, the circulation of the NEJM is magnitudes higher than Lancet. Also, if you give weight to these numbers, the "impact factor" as of 2020 for NEJM was 91. The impact factor for Lancet was 79.
NEJM comes in first and the Lancet comes in 2nd, but there is a big gap between the two.
NWBO needs that impact factor. They need eyeballs and they need the legitimacy that comes from a NEJM publication. That is why I'm keeping my fingers crossed for NEJM, but realize it could very well be a host of different journals. I'd also be very happy with the Lancet so I'm not against your choice, just have 1a as NEJM and 1b as Lancet.